Full text is available at the source.
Abstract
Long-term outcomes of adjunctive everolimus for TSC-associated epilepsy remain unclear.
- Everolimus is a medication that targets a specific protein involved in cell growth and regulation.
- The effectiveness of everolimus for reducing seizures in patients with tuberous sclerosis complex is being evaluated.
- Factors that may influence the success of everolimus treatment for seizures are being explored.
- Real-world data on long-term seizure outcomes with everolimus in this context is limited.
Simplified